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Introduction
Mycotoxin binders are commonly used in the feed additive industry to prevent mycotoxicosis in farm animals (Kolosova and Stroka, 2011). These products
are deemed to adsorb mycotoxins in the gut and consequently prevent mycotoxin absorption. Recently, the European Food Safety Authority (EFSA, 2010)
stated that too little is known about the interaction between mycotoxin binders and veterinary drugs. Therefore more studies are needed to investigate
possible interactions at the level of intestinal absorption. Some suggestions have been made about a possible interaction between macrolide antibiotics and
bentonite (EFSA, 2011), however no specific proof has been put forward yet. The Canadian Bureau of Veterinary Drugs (1992) reported a case of lack of
efficiency of tylosin when fed concurrently with bentonite to bovines. Shryock et al. (1994) reported that tilmicosin added to the diet in broiler chickens
prevented development of air-sacculitis after inoculation with Mycoplasma gallisepticum, whereas a combined use of tilmicosin and bentonite did not
prevent air-sac lesions or clinical symptoms, indicating a possible negative interaction between both. Therefore, the goal of this study was to investigate the
capacity of bentonite to bind tylosin, based on specific pharmacokinetic characteristics instead of clinical symptoms which can be biased.
Materials and methods
Sixteen 3 weeks-old broiler chickens (Ross 308) were randomly allocated in two groups of 8 birds. After a one-week acclimatization period, the animals were
famished for 12 h. This was followed by an oral intra-crop bolus. One group received a bolus of tylosin (24 mg/kg BW, Tylan Soluble, Elanco Animal Health).
The other group received a bolus of tylosin (24 mg/kg BW) and bentonite (0.1 g/kg BW) (Toxisorb Classic, Süd-Chemie). At several time-points after bolus
administration, blood was drawn and plasma concentrations of tylosin A were analyzed using a quantitative LC-MS/MS method (Devreese et al., 2012).
Plasma concentration-time profiles were evaluated (Figure 1) and several toxicokinetic parameters were calculated (WinNonlin 6.2, Pharsight Corp., USA)
and compared between groups (Table 1) in order to evaluate the tylosin binding capacity of bentonite clay.
Results
Table 1. Main pharmacokinetic parameters of tylosin after a single oral bolus administration of tylosin (24 mg/kg
BW) with or without bentonite (0.1 g/kg BW) to broiler chickens. Values are presented as mean ± SD (n=8)
Pharmacokinetic Parameter Tylosin Tylosin + Bentonite
AUC 0-inf (µg.h/mL)
17.06± 5.31 2.89 ± 1.14 **
Cmax (µg/mL)
7.08 ± 3.64 1.66 ± 0.77 **
Tmax (h)
3.00 ± 0.33 1.92 ± 0.42 *
kel (h
-1) 0.51 ± 0.08 0.59 ± 0.23
T1/2el (h)
1.42 ± 0.21 0.67 ± 0.99
Relative OBB (%) 23.3 ± 7.22 ***
AUC0-inf: area under plasma concentration-time profile from time 0 to infinite; Cmax: maximal plasma
concentration; Tmax: time to maximal plasma concentration; Kel: elimination rate constant; T1/2el:
elimination half-life; relative OBB: relative oral bioavailability; * p < 0.05, ** p < 0.01 and *** p < 0.001
Figure 1. Plasma concentration-time profile of tylosin A after a single oral bolus administration of tylosin (24 mg/kg BW) with or
without bentonite (0.1 g/kg BW) to broiler chickens. Values are presented as mean + SD (n=8)
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These results confirm the suggestion made by other authors (Canadian Bureau of Veterinary Drugs, 1992; EFSA, 2011; Shryock et al., 1994)
that bentonite is able to bind macrolide antibiotics. This was demonstrated by a significant alteration of following pharmacokinetic parameters
reflecting drug absorption due to the addition of bentonite to the oral bolus: area under the plasma concentration-time curve from time 0 to
infinite (AUC0-inf), maximal plasma concentration (Cmax), time to maximal plasma concentration (Tmax) and relative oral bioavailability (relative
OBB). The combined use of tylosin and bentonite in animal husbandry should therefore be avoided, as this interaction can have serious
consequences. Lowered plasma concentrations of antibiotics may implicate therapy failure and enhanced microbial resistance development.
Future research should be performed on the interaction with other veterinary drugs and different mycotoxin binders. This research should be
based on specific pharmacokinetic parameters instead of unspecific clinical symptoms, as only pharmacokinetic parameters can really prove a
decreased oral bioavailability of the drug, due to adsorption.
Discussion
